Authors' Reply: Renal Function and Adverse Maternal and Fetal Outcomes: New Evidence
- PMID: 37526985
- PMCID: PMC10402925
- DOI: 10.1681/ASN.0000000000000169
Authors' Reply: Renal Function and Adverse Maternal and Fetal Outcomes: New Evidence
Conflict of interest statement
M.A. Hladunewich reports Research Funding: Calliditas Therapeutics, Chemocentryx, Chinook, Ionis, Pfizer, and Roche; Honoraria: Uptodate; and Other Interests or Relationships: Medical Lead for Glomerular Disease Ontario Renal Network. The remaining author has nothing to disclose.
Comment on
-
Pre-Pregnancy eGFR and the Risk of Adverse Maternal and Fetal Outcomes: A Population-Based Study.J Am Soc Nephrol. 2023 Apr 1;34(4):656-667. doi: 10.1681/ASN.0000000000000053. Epub 2023 Jan 30. J Am Soc Nephrol. 2023. PMID: 36735377 Free PMC article.
-
Renal Function and the Adverse Maternal and Fetal Outcomes: New Evidence.J Am Soc Nephrol. 2023 Aug 1;34(8):1471. doi: 10.1681/ASN.0000000000000168. J Am Soc Nephrol. 2023. PMID: 37526984 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
